Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sonoma Pharmaceuticals Inc
Net Issuance of Debt
Sonoma Pharmaceuticals Inc
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Net Issuance of Debt
-$27k
|
CAGR 3-Years
64%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
15%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Issuance of Debt
$9.6B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Issuance of Debt
-$5.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-16%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Issuance of Debt
-$74m
|
CAGR 3-Years
72%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Issuance of Debt
$11.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
18%
|
CAGR 10-Years
13%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Issuance of Debt
$8.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
94%
|
CAGR 10-Years
N/A
|
|
Sonoma Pharmaceuticals Inc
Glance View
Sonoma Pharmaceuticals, Inc. engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company is headquartered in Woodstock, Georgia and currently employs 13 full-time employees. The company went IPO on 2007-01-26. The firm's product offerings include Epicyn Antimicrobial Facial Cleanser, Levicyn Antimicrobial Dermal Spray, Levicyn Antipruritic Gel, Levicyn Antipruritic Spray Gel, Celacyn Scar Management Gel and Sebuderm Topical Gel. Its products are primarily targeted at the treatment of acne, the management of scars and atopic dermatitis. The company also has its office dispense products, such as Lasercyn Dermal Spray, Lasercyn Post Procedure Gel and Regenacyn Advanced Scar Management. The firm sells its products either directly or via partners in approximately 54 countries across the world. Its subsidiaries include Aquamed Technologies, Inc., Oculus Technologies of Mexico, S.A. de C.V. and Sonoma Pharmaceuticals Netherlands B.V.
See Also
What is Sonoma Pharmaceuticals Inc's Net Issuance of Debt?
Net Issuance of Debt
-27k
USD
Based on the financial report for Dec 31, 2025, Sonoma Pharmaceuticals Inc's Net Issuance of Debt amounts to -27k USD.
What is Sonoma Pharmaceuticals Inc's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 10Y
15%
Over the last year, the Net Issuance of Debt growth was 39%. The average annual Net Issuance of Debt growth rates for Sonoma Pharmaceuticals Inc have been 64% over the past three years , and 15% over the past ten years .
